Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Agitation · Agitation,Psychomotor · BTAI

BioXcel Therapeutics

BioXcel Therapeutics clinical programs — 17 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
555 Long Wharf Dr, 12th floor, New Haven, Connecticut 06511, US HQ
2017 Founded
56 Employees
Public company Type
BTAI · NYSE Ticker
Company details
Status
Public
HQ
555 Long Wharf Dr, 12th floor, New Haven, Connecticut 06511, US
Founded
2017
Employees
56
Programs
17
Drugs
9
Patents
18
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BioXcel Therapeutics projects

17 ClinicalTrials.gov programs sponsored by BioXcel Therapeutics.

BioXcel Therapeutics has 17 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

17 programs

Clinical programs

  1. BXCL501

    BioXcel Therapeutics

    Agitation

    phase 3 small molecule completed

    4 trials

  2. BXCL501

    BioXcel Therapeutics

    Agitation,Psychomotor

    phase 3 small molecule completed

    1 trial

  3. Sublingual film containing Dexmedetomidine (BXCL501)

    BioXcel Therapeutics

    Agitation Associated With Bipolar Disorder

    phase 3 small molecule completed

    1 trial

  4. Sublingual film containing dexmedetomidine (BXCL501)

    BioXcel Therapeutics

    Agitation

    phase 3 small molecule completed

    1 trial

  5. BXCL501 Sublingual Film

    BioXcel Therapeutics

    Bipolar I Disorder

    phase 2 small molecule completed

    1 trial

  6. BXCL701

    BioXcel Therapeutics

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. BXCL701 plus Pembrolizumab

    BioXcel Therapeutics

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  8. Dexmedetomidine

    BioXcel Therapeutics

    Opioid Withdrawal

    phase 2 small molecule completed

    1 trial

  9. Dexmedetomidine sublingual film

    BioXcel Therapeutics

    Delirium

    phase 2 small molecule terminated

    1 trial

  10. Sublingual film containing Dexmedetomidine

    BioXcel Therapeutics

    Agitation,Psychomotor

    phase 2 small molecule completed

    1 trial

  11. BXCL501 80 Micrograms

    BioXcel Therapeutics

    Schizophrenia

    phase 1 small molecule active

    1 trial

  12. Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg

    BioXcel Therapeutics

    Alcohol Use Disorder (AUD)

    phase 1 small molecule active

    1 trial

  13. Placebo

    BioXcel Therapeutics

    Alcohol Use Disorder (AUD)

    phase 1 small molecule completed

    1 trial

  14. Sublingual film containing BXCL501 (Dexmedetomidine)

    BioXcel Therapeutics

    Agitation

    phase 1 small molecule completed

    1 trial

  15. Talabostat Mesylate

    BioXcel Therapeutics

    Cancer of Pancreas

    phase 1 small molecule terminated

    1 trial

  16. Dexmedetomidine

    BioXcel Therapeutics

    Schizophrenia Agitation

    approved small molecule active

    1 trial

  17. Sublingual film containing Igalmi

    BioXcel Therapeutics

    Bipolar Disorder

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does BioXcel Therapeutics have?

17 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.